More than 3,000 state and local governments will receive nearly $19 billion in payments from drugmakers and pharmacy chains in the most recent round of opioid settlements.
Featured Posts
The news comes months after activist investor Carl Icahn tried to place three of his representatives on Illumina’s board ahead of the company’s annual shareholder meeting last month. In his pitch, Icahn pointed to deSouza’s and the incumbent board’s failure “to take actions to maximize value for the company’s stockholders.”
“There could be around 10 total regulatory decisions this year on cell and gene therapies, including up to five decisions on gene therapies for rare genetic diseases alone,” said Stephen Majors, director of public affairs at the Alliance for Regenerative Medicine.
Chinook has a leading compound designed to treat IgA Nephropathy, or IgAN, a rare disease that can lead to kidney failure in young adults which has attracted a range of developers and is already the target of drug candidate developed by Novartis.
Shares of Biogen rose 4% in premarket trade on Monday as an unanimous backing of the company’s Alzheimer’s drug Leqembi by the U.S. regulator’s advisers eased concerns that a traditional approval for the treatment will not come with major new safety warnings.
As the number of rare disease drugs on the market exponentially increases, marketers will have to ramp up efforts to persuade payers of the value of these often costly treatments.
The first hearing in a German court case against BioNTech over side effects allegedly caused by its COVID-19 vaccine was postponed on Monday after the plaintiff’s lawyer petitioned for the case to be heard by different judges.
Blockbuster deals are on the rise as drug manufacturers navigate through patent cliffs, pricing pressures, and evolving regulations while M&A activity remains an integral part of the strategic landscape.
Although prescription drug pricing tends to dominate national media coverage – with a frequent focus on cost as a barrier to patient access – that is only one aspect of a complex and often convoluted experience for patients, especially when highly specialized treatments are needed.
Can recent breakthroughs in artificial intelligence (AI) accelerate the development of personalized medicine?